Search

Displaying results 2001 - 2010 of 6949 in total
  1. Drug

    Icatibant

    go.drugbank.com/drugs/DB06196
    ApprovedInvestigational

    [A4017,A263046] Icatibant was approved by the FDA on August 25, 2011, and by the EMA in 2008 as a treatment for hereditary angioedema. … results obtained from 3 double-blind, randomized, controlled clinical trials known as FAST 1, 2, and 3, where a median time to almost complete symptom relief was observed to be 8 hours compared to 36 hours for

    Categories: Bradykinin Receptor Antagonists, Bradykinin B2 Receptor Antagonists
  2. Drug

    Oteseconazole

    go.drugbank.com/drugs/DB13055
    ApprovedInvestigational

    [L41635] Unlike previous-generation azole antifungals, oteseconazole has a high selectivity for CYP51 and little interaction with human cytochrome P450s.

    Categories: Antimycotics for Systemic Use, Antiinfectives for Systemic Use
  3. Drug

    Amitriptyline

    go.drugbank.com/drugs/DB00321
    ApprovedInvestigational

    Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961.

    Categories: Antidepressive Agents Indicated for Depression, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  4. Drug

    Methyprylon

    go.drugbank.com/drugs/DB01107
    ApprovedIllicitWithdrawn

    Methyprylon is a sedative of the piperidinedione derivative family that was previously used for the treatment of insomnia.

  5. Drug

    Technetium Tc-99m oxidronate

    go.drugbank.com/drugs/DB09139
    ApprovedWithdrawn

    [L1139] Thus, technetium Tc-99m oxidronate is a powerful detection tool for abnormal osteogenesis by skeletal scintigraphy. … A radiopharmaceutical is defined as a medicinal formulation containing radioisotopes that are used in major clinical areas for diagnosis and/or therapy.

  6. Drug

    Carbopol 974P

    go.drugbank.com/drugs/DB05384
    ApprovedWithdrawn

    The compound, known as BufferGel, was in advanced clinical trials for its ability to prevent pregnancy, but was discontinued.

  7. Drug

    Mechlorethamine

    go.drugbank.com/drugs/DB00888
    ApprovedInvestigational

    The FDA granted marketing approval for the orphan drug Valchlor (mechlorethamine) gel on August 23, 2013 for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL

  8. Drug

    Ketoconazole

    go.drugbank.com/drugs/DB01026
    ApprovedInvestigational

    [A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981.

    Categories: Antifungals for Topical Use, Antimycotics for Systemic UseProducts: REKET - KETOCONAZOLCREMA 2%, REKET - KETOCONAZOL TABLETAS X 200 MG
  9. Drug

    Elafibranor

    go.drugbank.com/drugs/DB05187
    ApprovedInvestigational

    [L50768] On June 10, 2024, elafibranor was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis (PBC). … Elafibranor is a dual peroxisome proliferator-activated receptor (PPAR) α and β/δ agonist [A263833] that works to inhibit bile acid synthesis.

    Categories: Peroxisome Proliferator-activated Receptor Agonist
  10. Drug

    BNT162B2 Omicron (LP.8.1)

    go.drugbank.com/drugs/DB23337
    Approved

    BNT162B2 Omicron (LP.8.1) is the active ingredient in the 2025-2026 formulation of Pfizer and BioNTech's Comirnaty mRNA vaccine for COVID-19.